GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alkermes, Inc. (ALKS) [hlAlert]

Rating:
Buy ALKS
up 221.60 %

Alkermes, Inc. (ALKS) rated Buy by Citigroup

Posted on: Friday,  Oct 26, 2012  8:25 AM ET by Citigroup

Citigroup rated Buy Alkermes, Inc. (NASDAQ: ALKS) on 10/26/2012, when the stock price was $19.02. Since
then, Alkermes, Inc. has gained 221.61% as of 01/21/2016's recent price of $61.17.
If you would have followed this Citigroup's recommendation on ALKS, you would have gained 221.6% of your investment in 1182 days.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

Citi Investment Research is a highly respected research unit and is comprised of 390 research analysts across 22 countries. Citi Investment Research covers 3,100 companies, representing 90 percent of the market capitalization of the major global indices, and provides macro and quantitative analysis of global markets and sector trends. Combined with Citi's exceptional sales and trading capabilities and Smith Barney's financial consultants, the core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/26/2012 8:25 AM Buy
None
19.02
as of 12/31/2012
1 Week down  -3.64 %
1 Month down  -4.09 %
3 Months down  -2.62 %
1 YTD down  -2.62 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy